COMMUNIQUÉS West-GlobeNewswire

Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes
10/09/2026
TEL AVIV, Israel, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“ Teva ”) announced today that it successfully priced its offering of approximately $4.9 billion ( [...]
Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock
10/09/2026
ALACHUA, Fla. and TAMPA, Fla., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (“Axogen” or the “Company”) (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of [...]
Kestra Names Daniel Finney Vice President of Research & Development
10/09/2026
KIRKLAND, Wash., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, announced today that Daniel Finney has been named [...]
Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies
10/09/2026
Acquisition adds NerveTape™, the 1st FDA-approved device for sutureless peripheral nerve repair, broadening Axogen’s addressable market within its focus markets Axogen’s commercial infrastructure, surgeon relationships [...]
Syngenta and Amoéba Seal Exclusive European Distribution Deal, Aiming to Bring a Breakthrough Biofungicide to Cereal Growers
10/09/2026
Basel, Switzerland and Chassieu, France, Sept. 10, 2026 (GLOBE NEWSWIRE) -- The exclusive agreement will span the cereals market across the European Union, the United Kingdom, Ukraine and Switzerland, with first market [...]
CONNECTA Therapeutics Announces Financing to Advance Clinical Development of Fragile X Syndrome Program
10/09/2026
€3.1 million financing led by new investor Clave Capital, with participation from existing investors Proceeds will support completion of ongoing Phase IIa trial of CTH120 in Fragile X syndrome, with topline data readout [...]
Hexiris Ophthalmics to Present First-in-Human OBi Glaucoma Data at Five Fall Meetings, Beginning with the Ophthalmology Futures Forum in London
10/09/2026
Physician-founded company will bring its office-based interventional glaucoma platform to Ophthalmology Futures, ESCRS, Sally Letson, CGS and AAO 2026 DIEPPE, New Brunswick, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Hexiris [...]
VVMF, Australia's First Viral Vector CDMO Receives TGA Manufacturing Licence
10/09/2026
Regulatory milestone strengthens Australia’s sovereign advanced therapeutics manufacturing capability SYDNEY, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Viral Vector Manufacturing Facility Pty Ltd (VVMF), Australia’s first [...]
U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments
10/09/2026
If approved, Enspryng would be the first and only disease-modifying therapy for MOGAD (myelin oligodendrocyte glycoprotein antibody-associated disease) Filing acceptance is based on the Phase III METEOROID study showing [...]
Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting
10/09/2026
Initial results from RESTORE-PV show DISC-3405 increased hepcidin and lowered serum iron, translating to controlled hematocrit, reduced phlebotomy, and improved symptoms in PV patients DISC-3405 is the first monoclonal [...]
AdCare Hospital Expands Detox Services with New 12-Bed Unit, Helping More People Access Care in Worcester
09/09/2026
WORCESTER, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- For decades, AdCare Hospital has been a staple in the Worcester community, providing hospital-level detox services for people struggling with substance use disorders [...]
Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference
09/09/2026
CHICAGO and FORT WORTH, Texas, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for [...]
Venus Concept Announces CEO Transition
09/09/2026
TORONTO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”), a global medical aesthetic technology leader, today announced the appointment of Brad Oliver as Chief Executive Officer [...]
CooperCompanies Announces Third Quarter 2026 Results
09/09/2026
SAN RAMON, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal third quarter ended July 31, 2026. Revenue [...]
Crescent Biopharma Announces Grants of Inducement Awards
09/09/2026
WALTHAM, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma , Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies [...]
NANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
09/09/2026
PARIS and CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand [...]
NANOBIOTIX Participera à la Conférence H.C. Wainwright 28th Annual Global Investment
09/09/2026
PARIS and CAMBRIDGE, Mass., 09 sept. 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO – NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de développement clinique avancé, pionnière des [...]
CooperCompanies Completes Strategic Review, Increases Share Repurchase Authorization
09/09/2026
Board Unanimously Concludes to Retain CooperSurgical Expands Share Repurchase Authorization from $2 billion to $3 billion Board Remains Open to All Value Options that Create Shareholder Value SAN RAMON, Calif., Sept. 09 [...]
Century Therapeutics Appoints Joseph Truitt to Board of Directors
09/09/2026
PHILADELPHIA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune [...]

Pages